Patient WAIT Survey Findings Across 8 LATAM Countries

February 14, 2024

Back to all webinars

Open to all ISPOR Members and Non-members

Title: Patient WAIT Survey Findings Across 8 LATAM Countries

Wednesday, February 14, 2024
10:00AM EST | 3:00PM UTC | 4:00PM CET

Click here for time zone conversion

Register Now


During the webinar the speakers will present the FIFARMA W.A.I.T. indicator, which assesses the availability of innovative medicines for oncology and orphan diseases in 8 Latin American countries: Peru, Colombia, Chile, Mexico, Brazil, Costa Rica, Argentina, and Ecuador.

This study is the first survey based on the EFPIA (European Federation of Pharmaceutical Industries and Associations) Patients WAIT Indicator, which has been continuously evolving since 2004 in EU. FIFARMA has published for the Latin American region for the first time in 2022 and continued in its second version in 2023.

The survey offers valuable insights into the level of accessibility to cutting-edge medicines, aiming to provide a better understanding of the status of patient access across the region. Specifically focusing on oncology and orphan diseases, the survey delves into the challenges and opportunities related to obtaining innovative treatments, with the goal of promoting dialogue and driving positive changes to achieve equitable access to life-changing medications.

Learning Objectives

  • Show Actionable Information: Address one of the major challenges faced by healthcare systems: having actionable information regarding a key concern of decision-makers, which is the pressure of technological innovation.
  • Gain Insight into Relevant Information: Obtain relevant information concerning the approach to availability and the time it takes for a patient to access innovative medicines within a healthcare system, a concern of decision-makers.
  • Present General Information on Potential Bottlenecks for Access to Innovative Medicines post-FDA Approval: Provide an overview of potential bottlenecks that may hinder access to innovative medicines after FDA approval.


Diego Guarin, MD, Executive Director, Regional Market Access Latin America, MSD, Miami, FL, USA

Andre Ballalai, BSc, Associate Principal, Value & Access, IQVIA, New York, NY, USA

Oscar Courtney, BScManager, Value & Access, Strategy Consulting, IQVIA, Mexico City, Mexico

Francisca Rodriguez, MD, Value and Access to Innovation Co-chair, FIFARMA/CIF, Santiago, Chile

Aline Silveira Silva, PhD, Researcher, Aline Silva Consulting, University of British Columbia, Vancouver, BC, Canada

Yaneth Giha, MA, Executive Director, FIFARMA, Bogota, Columbia

Brought to you by: FIFARMA

Please note:
 On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 days after the scheduled Webinar.

Reservations are on a first-come, first-served basis.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now